Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 864-871

  Shorr, Andrew F ^a   Lodise, Thomas P ^b   Corey, G Ralph ^c   De Anda, Carisa ^d   Fang, Edward ^d   Das, Anita F ^d   Prokocimerd, Philippe ^d  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c DUKE UNIVERSITY HEALTH SYSTEM   (United States)

^d Cubist Pharmaceuticals ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; LINEZOLID; TEDIZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE; TETRAZOLE DERIVATIVE;

ABSCESS; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL SKIN DISEASE; CELLULITIS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; ERYSIPELAS; FATIGUE; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; MYCOSIS; NAUSEA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SIDE EFFECT; SKIN ABSCESS; SKIN STRUCTURE; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; WOUND INFECTION; CLINICAL TRIAL; SKIN DISEASES, BACTERIAL; SKIN DISEASES, INFECTIOUS; STAPHYLOCOCCAL SKIN INFECTIONS;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LINEZOLID; MALE; OXAZOLIDINONES; SKIN DISEASES, BACTERIAL; SKIN DISEASES, INFECTIOUS; STAPHYLOCOCCAL SKIN INFECTIONS; TETRAZOLES;

EID: 84921933187     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03688-14     Document Type: Article

References (34)

1. Taira BR, Singer AJ, Thode HC, Jr, Lee CC. 2009. National epidemiology of cutaneous abscesses: 1996 to 2005. Am J Emerg Med 27:289-292. http://dx.doi.org/10.1016/j.ajem.2008.02.027.
2. Hersh AL, Chambers HF, Maselli JH, Gonzales R. 2008. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 168:1585-1591. http://dx.doi.org/10.1001 /archinte.168.14.1585.
3. Moran GJ, Abrahamian FM, Lovecchio F, Talan DA. 2013. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J Emerg Med 44:e397-e412. http: //dx.doi.org/10.1016/j.jemermed.2012.11.050.
4. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC. 2005. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41:1373-1406. http://dx.doi.org /10.1086/497143.
5. Tracy LA, Furuno JP, Harris AD, Singer M, Langenberg P, Roghmann MC. 2011. Staphylococcus aureus infections in US veterans, Maryland, USA, 1999-2008. Emerg Infect Dis 17:441-448. http://dx.doi.org/10 .3201/eid1703.100502.
6. Talan DA, Krishnadasan A, Gorwitz RJ, Fosheim GE, Limbago B, Albrecht V, Moran GJ, EMERGEncy ID Net Study Group. 2011. Comparison of Staphylococcus aureus from skin and soft-tissue infections in US emergency department patients, 2004 and 2008. Clin Infect Dis 53:144-149. http://dx.doi.org/10.1093/cid/cir308.
7. Dukic VM, Lauderdale DS, Wilder J, Daum RS, David MZ. 2013. Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis. PLoS One 8:e52722. http://dx .doi.org/10.1371/journal.pone.0052722.
8. European Centre for Disease Prevention and Control. 2013. Surveillance Report: antimicrobial resistance surveillance in Europe. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). 2012. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden. http://ecdc.europa.eu/en/ publications/Publications/antimicrobial-resistance-surveillance -europe-2012.pdf.
9. Jones RN, Guzman-Blanco M, Gales AC, Gallegos B, Castro AL, Martino MD, Vega S, Zurita J, Cepparulo M, Castanheira M. 2013. Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011). Braz J Infect Dis 17:672-681. http://dx.doi .org/10.1016/j.bjid.2013.07.002.
10. Kang CI, Song JH. 2013. Antimicrobial resistance in Asia: current epidemiology and clinical implications. Infect Chemother 45:22-31. http://dx .doi.org/10.3947/ic.2013.45.1.22.
11. Berger A, Oster G, Edelsberg J, Huang X, Weber DJ. 2013. Initial treatment failure in patients with complicated skin and skin structure infections. Surg Infect (Larchmt) 14:304-312. http://dx.doi.org/10.1089 /sur.2012.103.
12. Davis SL, Perri MB, Donabedian SM, Manierski C, Singh A, Vager D, Haque NZ, Speirs K, Muder RR, Robinson-Dunn B, Hayden MK, Zervos MJ. 2007. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 45: 1705-1711. http://dx.doi.org/10.1128/JCM.02311-06.
13. Labreche MJ, Lee GC, Attridge RT, Mortensen EM, Koeller J, Du LC, Nyren NR, Treviño LB, Treviño SB, Peña J, Mann MW, Muñoz A, Marcos Y, Rocha G, Koretsky S, Esparza S, Finnie M, Dallas SD, Parchman ML, Frei CR. 2013. Treatment failure and costs in patients with methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STARNet) study. JAmBoard FamMed 26:508-517. http://dx.doi.org/10.3122/jabfm .2013.05.120247.
14. Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, Mai TT, Vo NH, Dang DN, Phan TH, Basuino L, Perdreau-Remington F, Chambers HF, Diep BA. 2012. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis 55:781-788. http://dx.doi.org/10.1093/cid/cis527.
15. Locke JB, Zurenko GE, Shaw KJ, Bartizal K. 2014. Tedizolid for the management of human infections: in vitro characteristics. Clin Infect Dis 58(Suppl 1):S35-S42. http://dx.doi.org/10.1093/cid/cit616.
16. Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D, Zurenko G. 2008. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 52:4442-4447. http://dx.doi.org/10.1128 /AAC.00859-08.
17. Locke JB, Hilgers M, Shaw KJ. 2009. Novel ribosomal mutations in Staphylococcus aureus strains identified through selection with the oxazolidinones linezolid and torezolid (TR-700). Antimicrob Agents Chemother 53:5265-5274. http://dx.doi.org/10.1128/AAC.00871-09.
18. Flanagan S, Fang E, Muñoz KA, Minassian SL, Prokocimer PG. 2014. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy 34: 891-900. http://dx.doi.org/10 .1002/phar.1458.
19. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. 2013. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309:559-569. http://dx.doi.org/10.1001/jama.2013.241.
20. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. 2014. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase III, non-inferiority trial. Lancet Infect Dis 14:696-705. http://dx.doi .org/10.1016/S1473-3099(14)70737-6.
21. U.S. Food and Drug Administration. 2013. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. U.S. Food and Drug Administration, Silver Spring, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/UCM071185.pdf.
22. European Medicines Agency. 2013. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu /docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003417.pdf.
23. Fang E, De Anda C, Das AF, Prokocimer P. 2014. Concordance between early and late response in ESTABLISH-1 and ESTABLISH-2: pooled results from two tedizolid phase 3 trials in acute bacterial skin and skin structure infection, ePoster eP434. Abstr 24th Annu Meet Eur Congr Clin Microbiol Infect Dis (ECCMID 2014), 10 to 13 May 2014, Barcelona, Spain.
24. National Institutes of Health (NIH). 2007. Division of Microbiology and Infectious Diseases (DMID) adult toxicity table. National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD. http://www.niaid.nih.gov/LabsAndResources/resources/DMIDClin Rsrch/Documents/dmidadulttox.pdf.
25. Prokocimer P, Bien P, Muñoz KA, Aster R. 2008. Hematological effects of TR-701, linezolid and placebo administered for 21 days in healthy subjects, poster F1-2069a. Abstr 48th Annu Intersci Conf Antimicrob Agents Chemother Infect Dis SocAm46th Annu Meet (ICAAC/IDSA 2008), 25 to 28 October 2008, Washington, DC.
26. Shaw KJ, Barbachyn MR. 2011. The oxazolidinones: past, present, and future. Ann N Y Acad Sci 1241:48-70. http://dx.doi.org/10.1111/j.1749 -6632.2011.06330.x.
27. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ, Martin JJ, Groote CC, Vandecasteele S, Boelaert JR. 2006. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 42:1111-1117. http://dx.doi.org/10.1086/501356.
28. Pfizer. 2014. Zyvox (linezolid) injection, tablets and oral suspension. Pharmacia & Upjohn Co. Division of Pfizer, Inc., New York, NY. http: //labeling.pfizer.com/ShowLabeling.aspx?id=649.
29. Lemaire S, Van Bambeke F, Appelbaum PC, Tulkens PM. 2009. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother 64:1035-1043. http://dx.doi .org/10.1093/jac/dkp267.
30. Garrabou G, Soriano A, López S, Guallar JP, Giralt M, Villarroya F, Martínez JA, Casademont J, Cardellach F, Mensa J, Miró O. 2007. Reversible inhibition of mitochondrial protein synthesis during linezolidrelated hyperlactatemia. Antimicrob Agents Chemother 51:962-967. http: //dx.doi.org/10.1128/AAC.01190-06.
31. Flanagan S, Minassian SL, Muñoz KA, Dreskin H, Fang E, Prokocimer P. Lack of pharmacokinetic drug interaction of tedizolid phosphate with pseudoephedrine in healthy subjects, poster P-921. Abstr 23rd Annu Meet Eur Congr Clin Microbiol Infect Dis (ECCMID 2013), 27 to 30 April 2013, Berlin, Germany.
32. Tanaka T, Hayashi Y, Okumura K, Yoshikawa K, Kato M, Kanatani KT, Ikushima I. Changes in intestinal flora during 7-day tedizolid phosphate administration in a phase I study in healthy Japanese subjects, poster P1675. Abstr 24th Eur Soc Clin Microbiol Infect Dis (ECCMID 2014), 10 to 13 May 2014, Barcelona, Spain.
33. Lode H, Von der Höh N, Ziege S, Borner K, Nord CE. 2001. Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. Scand J Infect Dis 33:899-903. http://dx.doi.org/10.1080 /00365540110076714.
34. Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society. 2012. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 33:322-327. http://dx.doi.org/10.1086/665010.